

Sponsor: Sanofi	
Product Code: GZ419828	Product INN: AGALSIDASE BETA
Study Code: LPS15918	EUDRACT Number: 2019-000064-21
Title of the study: A Randomized, Open-label, Active Comparator, 2-arm, Prospective Study to Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease	

Study Status: No patient screened, no patient randomized, no patient exposed to the treatment at the time of the study premature stop.

Reason of early termination: The Sponsor terminated the study due to recruitment infeasibility without having enrolled any patient.